Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein L22 pseudogene 1 (MRPL22P1) is a pseudogene in the human genome corresponding to the functional gene encoding mitochondrial ribosomal protein L22, which is a component of the 39S large subunit of the mitochondrial ribosome[1][2][4][5][8]. As a pseudogene, MRPL22P1 does not produce a functional protein product and is generally not considered to have a direct biological function, molecular activity, disease association, or therapeutic relevance. Pseudogenes are typically regarded as "genomic fossils"—remnants of once-functional genes—and are not considered therapeutic targets[1][2][8]. MRPL22P1 is distinct from the closely related functional genes such as MRPL22 (the actual mitochondrial ribosomal protein L22 gene) or RPL22L1 (ribosomal protein L22-like 1 gene), which are functional protein-coding genes with roles in mitochondrial protein synthesis and, in the case of RPL22L1, possible disease associations[3][6][7]. Key points: - MRPL22P1 is a non-coding, non-functional pseudogene and does not encode a receptor, enzyme, transporter, or any active protein[1][2][8]. - It has no established biological functions, disease roles, biomarkers, nor does it interact with drugs, and is not relevant as a therapeutic or biomarker target. - If you are seeking information on a potential drug target or protein with relevant functions, it is likely you meant MRPL22 (mitochondrial ribosomal protein L22) or RPL22L1 (ribosomal protein L22-like 1), not MRPL22P1 (the pseudogene)[1][2][4][7][8]. If further information is needed on the functional mitochondrial ribosomal protein L22 or its variants, please clarify or request information for MRPL22 or RPL22L1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein L22 pseudogene 1 (MRPL22P1).